. . . .which is why this sort of e-mail traffic is so unfortunate — here, the Lead Medical Investigator of the ENHANCE study (Dr. Kastelein) is trying to get a meeting scheduled with Schering-Plough and Merck executives, to go through ENHANCE issues, and apparently, the ball has been dropped on scheduling the meeting — things aren’t progressing. So, one of the executives asks about the “level of priority” on the project, at the Schering-Plough Research Institute (or “SPRI”, below) — remember, this is about a year and a half after the study was completed. Profanity ensues. As ever, click to enlarge:
This sort of traffic might lead one to wonder whether SPRI executives had some “additional motivation” in not promptly following-up on these presumably-proper requests — from the study’s lead medical investigator, no less — to schedule an important meeting.